Zealand Pharma A/S (ZLDPF) Expected to Announce Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF) is expected to announce its results before the market opens on Thursday, February 19th. Analysts expect the company to announce earnings of ($1.34) per share for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.21. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. The firm had revenue of $7.76 million for the quarter, compared to analysts’ expectations of $4.54 million. On average, analysts expect Zealand Pharma A/S to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Zealand Pharma A/S Price Performance

Shares of OTCMKTS ZLDPF opened at $63.84 on Thursday. The firm has a market cap of $4.53 billion, a P/E ratio of 4.59 and a beta of 0.72. Zealand Pharma A/S has a twelve month low of $49.98 and a twelve month high of $108.30. The company has a quick ratio of 14.10, a current ratio of 14.10 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $70.67 and a 200 day moving average of $70.18.

Analysts Set New Price Targets

A number of brokerages have weighed in on ZLDPF. BTIG Research raised Zealand Pharma A/S to a “strong-buy” rating in a research report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a report on Tuesday, December 16th. Five analysts have rated the stock with a Strong Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.